![]() | |
Clinical data | |
---|---|
Trade names | Lutathera |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
Drug class | Radiolabeled somatostatin analog |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C65H87LuN14O19S2 |
Molar mass | 1607.58 g·mol−1 |
3D model (JSmol) | |
| |
|
Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors.[5] It is a radiolabeled somatostatin analog.[3][6][7]
Alternatives to 177Lu-dotatate include yttrium-90 dotatate or DOTATOC. The longer range of the beta particles emitted by 90Y, which deliver the therapeutic effect, may make it more suitable for large tumors with 177Lu reserved for smaller volumes[8][9]
The US Food and Drug Administration (FDA) considers 177Lu dotatate to be a first-in-class medication.[10]
Lutathera EPAR
was invoked but never defined (see the help page).FDA PR
was invoked but never defined (see the help page).FDA PR 2
was invoked but never defined (see the help page).